ArticleBritish journal of haematology2014

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.

Olga Frolova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.